Dupilumab Improves Endoscopic Features in Children Aged 1-11 Years With Eosinophilic Esophagitis: EoE KIDS Study Results.

Authors

Shauna Schroeder, Mirna Chehade, Calies Menard-Katcher, Navneet Virk Hundal, Ruiqi Liu, Changming Xia, Lacey B Robinson, Jennifer Maloney, Margee Louisias, Allen Radin

Published in

The American journal of gastroenterology. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

This post hoc analysis assessed the impact of dupilumab on endoscopic features of eosinophilic esophagitis (EoE) using the Endoscopic Reference Score (EREFS) in children 1-11 years of age in the phase 3 EoE KIDS trial.
Patients who received weight-tiered higher-exposure (HE) dupilumab (N=37) or placebo (N=34) for 16 weeks (Part A) and weight-tiered HE dupilumab for 36 additional weeks (N=55) (Part B) in EoE KIDS were included. Change from baseline in EREFS total score, EREFS inflammation and fibrostenotic subscores, component scores, and proportion of patients achieving endoscopic normalization (EREFS total score of 0), were assessed at Week 16 and Week 52.
At Week 16, EREFS total score and inflammation subscore were reduced with dupilumab vs placebo (LS mean difference -66.9% [95% CI -89.8, -44.0] and -2.2% [-2.7, -1.8], respectively); improvements in features of fibrostenosis were limited (-0.2% [-0.5, 0.1]), partly due to low baseline scores in these features. At Week 52, outcomes were maintained or further improved in patients continuing dupilumab and improved in placebo patients who switched to dupilumab at Week 16. Continuous dupilumab treatment for 52 weeks led to a greater proportion of patients in endoscopic normalization vs switching to dupilumab at Week 16 (30.3% vs 12.5%).
Dupilumab improved endoscopic features of EoE at Week 16 vs placebo, and improvements were sustained up to 52 weeks. A greater proportion of patients treated with continuous dupilumab achieved endoscopic normalization at Week 52 compared with those who switched to dupilumab at Week 16.

PMID:
42430733
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.